Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (171-180 of 250) with videos related to

Pageof 25
Sort By:
Clinical Immunology (Orlando, Fla.)|June 22, 2024
Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer: Clinical potential and efficacy in EGFR mutation subsetsHyun Lee, Miseon Lee, Chae Lyul Lim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 21, 2020
Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective studyHyung-Don Kim, Yeonghak Bang, Myung Ah Lee, et al.
The Annals of Thoracic Surgery|September 11, 2012
Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancerChanghoon Yoo, Ji Hyun Park, Dok Hyun Yoon, et al.
Therapeutic Advances in Medical Oncology|September 7, 2019
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study GroupChanghoon Yoo, Hyeon-Su Im, Kyu-Pyo Kim, et al.
Cancer Research and Treatment|February 6, 2020
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for ResponseJunho Kang, Jae Ho Jeong, Hee-Sang Hwang, et al.
Therapeutic Advances in Medical Oncology|May 23, 2022
Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysisYeong Hak Bang, Choong-Kun Lee, Changhoon Yoo, et al.
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
Lancet (London, England)|June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
International Journal of Surgery (London, England)|March 27, 2024
Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancerWoohyung Lee, Minyoung Oh, Jae Seung Kim, et al.
Targeted Oncology|March 1, 2021
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched AnalysisYeonghak Bang, Changhoon Yoo, Sara Lonardi, et al.
Pageof 25

Showing results (171-180 of 250) with videos related to

Sort By:
Pageof 25
Clinical Immunology (Orlando, Fla.)|June 22, 2024
Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer: Clinical potential and efficacy in EGFR mutation subsetsHyun Lee, Miseon Lee, Chae Lyul Lim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 21, 2020
Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective studyHyung-Don Kim, Yeonghak Bang, Myung Ah Lee, et al.
The Annals of Thoracic Surgery|September 11, 2012
Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancerChanghoon Yoo, Ji Hyun Park, Dok Hyun Yoon, et al.
Therapeutic Advances in Medical Oncology|September 7, 2019
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study GroupChanghoon Yoo, Hyeon-Su Im, Kyu-Pyo Kim, et al.
Cancer Research and Treatment|February 6, 2020
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for ResponseJunho Kang, Jae Ho Jeong, Hee-Sang Hwang, et al.
Therapeutic Advances in Medical Oncology|May 23, 2022
Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysisYeong Hak Bang, Choong-Kun Lee, Changhoon Yoo, et al.
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
Lancet (London, England)|June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
International Journal of Surgery (London, England)|March 27, 2024
Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancerWoohyung Lee, Minyoung Oh, Jae Seung Kim, et al.
Targeted Oncology|March 1, 2021
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched AnalysisYeonghak Bang, Changhoon Yoo, Sara Lonardi, et al.
Pageof 25